785O PIVOT IO 001: First disclosure of efficacy and safety of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) vs NIVO monotherapy in advanced melanoma (MEL)

作者：Adi Diab, Helen Gogas, Shahneen Sandhu, Georgina V. Long, Paolo A. Ascierto, James Larkin, Mario Sznol, Fábio Franke, T-E. Ciuleanu, E. Muñoz Couselo, A. Perfetti, Célèste Lebbé, Friedegund Meier, Brendan D. Curti, C. Rojas, Hwai‐I Yang, Ming Zhou, Shruthi Ravimohan, Mary Tagliaferri, N. Khushanlani · 发表于：Annals of Oncology · 年份：2022 · DOI：10.1016/j.annonc.2022.07.911 · 被引用次数：12 · 研究领域：Cancer Immunotherapy and Biomarkers、CAR-T cell therapy research、Immunotherapy and Immune Responses